Company profile

Shenzhen Salubris Pharmaceuticals

002294 · SZSE · China

Public Market Listing

002294SZSE

SZSE primary exchange listing

Live quotes, historical charts, and market capitalization for Shenzhen Salubris Pharmaceuticals are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(7 total)
7Total Assets
1Approved
2Phase 3 / Filed
4Phase 1–2 / Early
4Diseases
Quick filter:
Showing 7 of 7 assets
Target & Modality
Enarodustat
Approved
HIF prolyl hydroxylase (HIF-PH1/2/3)Small molecule
Chronic Kidney Disease
SAL003
Phase 3
PCSK9Monoclonal antibody
Atherosclerotic Cardiovascular Disease
SAL0150No recent activity
Phase 3
GLP-1 receptorSmall molecule
Type 2 Diabetes
JK07
Phase 2
ErbB2/ErbB4 (neuregulin pathway)Biologic — subtype unspecified
Heart Failure
SAL0120
Phase 2
Endothelin receptor type A (ETA)Small molecule
Chronic Kidney Disease
SAL0137
Phase 2
Apolipoprotein(a) [apo(a)] / apo(a)-apoB100 interactionSmall molecule
Atherosclerotic Cardiovascular Disease
SAL0140
Phase 2
Aldosterone synthase (CYP11B2)Small molecule
Chronic Kidney Disease

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.